-
Use Cases
-
Resources
-
Pricing
2010
% complete
Federal jury ruled that Medtronic CoreValve LLC willfully infringed on the U.S. Andersen transcatheter heart valve patent, owned by Edwards. Damages were awarded to Edwards
November 2011
% complete
FDA approves Edwards Sapien valve
2013
% complete
Medtronic pays Edwards $84 million in initial damages for pending case
October 2013
% complete
CoreValve U.S. pivotal trial data presented at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) conference. This trial’s first results were very positive. For patients in which traditional open-heart surgery was too much of a risk, the CoreValve system showed to reduce the rate of death or major stroke by 40.7% compared to patients treated with standard therapy.
January 15, 2014
% complete
Jury in Federal District Court of Delaware decides the Medtronic CoreValve infringes on Edwards’ U.S. Cribier transcatheter heart valve patent (U.S. Pat. No. 8,002,825). Edwards was awarded $394 million in damages. Medtronic moves to appeal decision
January 17, 2014
% complete
FDA approval of CoreValve System for inoperable patients after review of U.S. Pivotal trial
April 14, 2014
% complete
Injunction issued by federal court barring Medtronic from selling recently approved CoreValve product
April 21, 2014
% complete
Injunction decision postponed
May 20, 2014
% complete
Global patent license settlement between Medtronic and Edwards. All pending litigation matters and patent office actions dismissed by both parties, Medtronic will pay Edwards $750 million, along with ongoing royalty payments of no less than $40 million annually until April 2022. Both parties agreed that they will not sue each other for patent matters anywhere in the world for eight years in the field of aortic and other transcatheter heart valves